Q2 2026 Viatris Inc Earnings Call Transcript
Key Points
- Viatris Inc (VTRS) delivered strong Q2 2026 results with total revenues of $3.8 billion, representing 3.5% operational growth year-over-year, and raised its full-year 2026 guidance across all key financial metrics.
- The company's Greater China segment continues to outperform, with net sales increasing 16% year-over-year, driven by strong demand for cardiovascular products and successful e-commerce and retail investments.
- The R&D pipeline is advancing well, highlighted by the FDA approval of Gwyn Lo, positive Phase 3 results for Nefecon in Japan, and on-track Phase 3 programs for Selatogrel and Cenerimod with readouts expected in 2027.
- The enterprise-wide strategic review is delivering cost savings ahead of schedule, leading to improved operating leverage and a 1% year-over-year improvement in adjusted gross margin to 57.5%.
- The company maintains a strong balance sheet with a gross leverage ratio of 2.9 times, and has deployed approximately $1.4 billion in capital, including $550 million returned to shareholders via dividends and buybacks.
- The complex generics portfolio, particularly transdermal patches and injectables, is experiencing strong demand, with the company expanding capacity to meet unprecedented growth in the estradiol patch market.
- The company faces ongoing supply disruptions at its Nashik facility, following a Q1 fire and FDA inspection observations, which are expected to impact total revenues by $100 million to $150 million in the second half of 2026.
- Greater China growth is expected to moderate in the second half due to a new procurement policy change that could negatively impact volumes in the hospital channel, with execution varying across provinces.
- Developed Markets face anticipated competitive pressures, including on key products like Breyna and Wixella in North America, which could impact high-margin revenue streams.
- Emerging Markets net sales declined 2% year-over-year, below expectations, primarily due to continued supply constraints affecting the lower-margin ARV generics portfolio.
- The JANZ segment is expected to decline low-single digits for the full year, impacted by government-driven price regulations in Japan and increased competition for certain brands in Australia.
- The company anticipates a moderation in overall growth rates, with total revenue growth expected to slow to approximately 2% operationally for the full year, down from the 3.5% seen in Q2.
Good morning, everyone, and welcome to the Viatris Q2 2026 earnings call. (Operator Instructions) Please also note today's event is being recorded.
At this time, I'd like to turn the floor over to Bill Szabloski, Head of Capital Markets. Sir, please go ahead.
Good morning, everyone. Welcome to our Q2 2026 earnings call. With us today is CEO, Scott Smith; Interim CFO, Paul Campbell; Chief R&D Officer, Philippe Martin, and Chief Commercial Officer, Corinne Milgoff.
During today's call, we will be making forward-looking statements on a number of matters, including our financial guidance for 2026 and various strategic initiatives. These statements are subject to risks and uncertainties. We will also be referring to certain actual and projected non-GAAP financial measures. Please refer to today's slide presentation and our SEC filings for more information. Including reconciliations of those non-GAAP measures to most directly comparable GAAP measures.
When discussing 2026 actual
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
